No Data
No Data
Ascendiant Maintains GRI Bio(GRI.US) With Buy Rating
Express News | GRI Bio Inc : Ascendiant Capital Markets Cuts Target Price to $40 From $221
GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference
H.C. Wainwright Initiates GRI Bio(GRI.US) With Buy Rating, Announces Target Price $10
Promising Prospects for GRI Bio: Matthew Keller's Buy Rating on GRI-0621 Amid Positive Phase 2a Safety Data
Express News | HC Wainwright & Co. Reiterates Buy on GRI Bio, Maintains $10 Price Target